D Conlon - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

D Conlon

Showing results (61-70 of 63) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 63 results.

Anti-Cancer Drug Design|June 1, 1996

Bis-naphthalimides 3: synthesis and antitumor activity of N,N'-bis[2-(1,8-naphthalimido)-ethyl] alkanediaminesM F Braña, J M Castellano, M Morán, et al.

Advances in Therapy|September 3, 2016

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade<sup>®</sup> (Infliximab)Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 24, 2015

Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemiaMeili Zhang, Lesley A Mathews Griner, Wei Ju, et al.

Pageof 7

Search research articles

Showing results (61-70 of 63) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 63 results.

Anti-Cancer Drug Design|June 1, 1996

Bis-naphthalimides 3: synthesis and antitumor activity of N,N'-bis[2-(1,8-naphthalimido)-ethyl] alkanediaminesM F Braña, J M Castellano, M Morán, et al.

Advances in Therapy|September 3, 2016

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade<sup>®</sup> (Infliximab)Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 24, 2015

Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemiaMeili Zhang, Lesley A Mathews Griner, Wei Ju, et al.

Pageof 7